The Science is There: Key Considerations for Stabilizing Viral Vector-Based Covid-19 Vaccines

Area of Science:

• Vaccinology
• Biopharmaceutical Formulation
• Public Health

Background:

• Global distribution of 5-10 billion Covid-19 vaccine doses presents significant logistical challenges.
• Viral vector-based vaccines require careful consideration of stability for storage and administration.

Purpose of the Study:

• To discuss strategies for addressing the distribution, storage, and administration challenges of viral vector-based Covid-19 vaccines.
• To leverage past experiences with live attenuated virus and viral vector vaccines to inform Covid-19 vaccine development.

Main Methods:

• Reviewing formulation development experience for live attenuated virus vaccines.
• Analyzing stability data for replication-competent and replication-deficient viral vector vaccines.
• Considering lessons learned from decades of vaccine development and manufacturing.

Main Results:

• Traditional live virus vaccines have achieved long shelf-lives through freeze-drying and refrigerated storage (2-8°C).
• Pandemic scenarios may necessitate liquid formulations with shorter shelf-lives (months) stored at 2-8°C for rapid distribution.
• Past formulation experience offers rapid solutions for Covid-19 vaccine stability challenges.

Conclusions:

• Decades of experience in live virus vaccine formulation are crucial for overcoming Covid-19 vaccine stability challenges.
• Adapting strategies from older vaccine types can expedite the development of stable and distributable Covid-19 vaccines.
• Understanding historical stability data is the most direct route to effective Covid-19 vaccine deployment.